Considering that SKA1 was overexpressed in grade IV glioma, we used Chinese Glioma Genome Atlas (CGGA) dataset to determine whether SKA1 could be used as a biomarker to distinguish between GBM and non-GBM patients (Grade II and III). The gene discussed is SKA1; the disease is central nervous system cancer.